GlassScriptPhysician profile
Richard A Carter
NPI 1083660104
$8,614.30
in general payments reported to CMS, 2019-2025
57 companies · $1,902 in 2025
The $1,902 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $205 · 2021: $258 · 2022: $964 · 2023: $2,353 · 2024: $1,781 · 2025: $1,902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,745 · Education: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,744.90 |
| Education | $291.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $691.58 | 2019-2025 | Lynparza, Tagrisso |
| Intuitive Surgical, INC. | $523.64 | 2019 | |
| Pfizer INC. | $491.43 | 2019-2025 | |
| Janssen Biotech, INC. | $433.36 | 2019-2025 | Darzalex, Rybrevant, Imbruvica |
| Beigene USA, INC. | $344.21 | 2023-2025 | Brukinsa, Tevimbra |
| Merck Sharp & Dohme LLC | $328.10 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $311.91 | 2019-2025 | Polivy, Lunsumio, Phesgo |
| Seagen INC. | $311.54 | 2022-2025 | Adcetris, Padcev, Tukysa |
| Sirtex Medical INC | $304.18 | 2022-2024 | Sir-Spheres Microspheres |
| Daiichi Sankyo INC. | $303.78 | 2023-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $297.31 | 2019-2025 | |
| Genzyme Corporation | $281.08 | 2022-2025 | |
| Exelixis INC. | $254.94 | 2020-2023 | Cabometyx |
| Glaxosmithkline, LLC. | $235.53 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| E.R. Squibb & Sons, L.L.C. | $230.52 | 2022-2023 | Opdualag |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $198.93 | 2021-2025 | Ninlaro, Fruzaqla, Iclusig |
| Array Biopharma INC | $196.26 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Alexion Pharmaceuticals, INC. | $194.88 | 2022-2025 | Ultomiris |
| Stemline Therapeutics INC. | $176.53 | 2023-2025 | Orserdu, Elzonris |
| Bayer Healthcare Pharmaceuticals INC. | $175.52 | 2022-2025 | |
| Eisai INC. | $165.26 | 2023-2025 | |
| Sobi, INC | $158.86 | 2022-2024 | |
| Lilly USA, LLC | $154.99 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $152.22 | 2020-2025 | Padcev, Vyloy |
| Abbvie INC. | $146.59 | 2022-2025 | Venclexta |
| Ipsen Biopharmaceuticals, INC | $140.68 | 2019-2024 | Tazverik |
| Celgene Corporation | $139.28 | 2023-2025 | Opdualag, Reblozyl |
| Gilead Sciences, INC. | $115.32 | 2022-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $112.19 | 2022-2024 | Monoferric |
| Medtronic USA, INC. | $102.67 | 2019 | |
| Beone Medicines USA, INC. | $87.28 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $66.19 | 2022-2023 | Tavalisse, Rezlidhia |
| Puma Biotechnology, INC. | $64.62 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $63.53 | 2020-2025 | Erleada |
| Jazz Pharmaceuticals INC. | $61.56 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $56.65 | 2024-2025 | Xpovio |
| Foundation Medicine, INC. | $44.53 | 2023 | |
| Dendreon Pharmaceuticals LLC | $44.42 | 2023 | Provenge |
| Amgen INC. | $40.35 | 2019-2023 | Lumakras |
| Pharmaessentia USA Corporation | $37.24 | 2024 | Besremi |
| Agios Pharmaceuticals, INC. | $35.49 | 2023-2024 | Pyrukynd |
| Taiho Oncology, INC. | $29.94 | 2022 | |
| Caris Mpi, INC. | $25.99 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $25.09 | 2023 | Krazati |
| Aveo Pharmaceuticals, INC. | $24.98 | 2022 | |
| Kyowa Kirin, INC. | $22.68 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $20.55 | 2022 | |
| Coherus Oncology, INC. | $20.33 | 2022 | |
| Global Blood Therapeutics, INC. | $20.02 | 2022 | |
| Acrotech Biopharma INC. | $19.99 | 2022 | |
| Myriad Genetic Laboratories, INC. | $19.78 | 2025 | Myrisk |
| Incyte Corporation | $19.32 | 2022 | |
| G1 Therapeutics, INC. | $19.09 | 2023 | Cosela |
| Cti Biopharma Corp. | $19.01 | 2023 | Vonjo |
| Mylan Institutional INC. | $18.99 | 2019 | |
| Tesaro, INC. | $16.96 | 2019 | |
| Deciphera Pharmaceuticals INC. | $16.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.